A. Gerl

5.7k total citations
74 papers, 2.7k citations indexed

About

A. Gerl is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, A. Gerl has authored 74 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Surgery, 25 papers in Pulmonary and Respiratory Medicine and 22 papers in Neurology. Recurrent topics in A. Gerl's work include Testicular diseases and treatments (62 papers), Neuroblastoma Research and Treatments (22 papers) and Sarcoma Diagnosis and Treatment (20 papers). A. Gerl is often cited by papers focused on Testicular diseases and treatments (62 papers), Neuroblastoma Research and Treatments (22 papers) and Sarcoma Diagnosis and Treatment (20 papers). A. Gerl collaborates with scholars based in Germany, United States and United Kingdom. A. Gerl's co-authors include J. Beyer, Lothar Kanz, Carsten Bokemeyer, W. Wilmanns, C. Clemm, Sophie D. Fosså, Hans‐Joachim Schmoll, Craig R. Nichols, R. Lamerz and Alan Horwich and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

A. Gerl

71 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Gerl Germany	32	2.2k	913	745	544	457	74	2.7k
J. Nicholls United Kingdom	17	1.4k 0.6×	387 0.4×	497 0.7×	483 0.9×	397 0.9×	30	1.8k
Pat Cook United Kingdom	14	1.7k 0.8×	406 0.4×	1.1k 1.5×	471 0.9×	424 0.9×	23	2.3k
Nicola Nicolai Italy	29	2.4k 1.1×	341 0.4×	771 1.0×	428 0.8×	526 1.2×	159	2.8k
Oliver Rick Germany	24	999 0.5×	473 0.5×	291 0.4×	312 0.6×	338 0.7×	92	1.7k
Melvin L. Samuels United States	28	1.5k 0.7×	313 0.3×	1.1k 1.5×	346 0.6×	483 1.1×	44	2.5k
Luigi Piva Italy	29	1.8k 0.8×	305 0.3×	928 1.2×	294 0.5×	651 1.4×	130	2.6k
Jillian R. Mann United Kingdom	27	905 0.4×	518 0.6×	361 0.5×	155 0.3×	447 1.0×	82	2.2k
J Bernard France	20	1.1k 0.5×	544 0.6×	322 0.4×	396 0.7×	347 0.8×	79	2.2k
Alessandro Inserra Italy	25	870 0.4×	351 0.4×	498 0.7×	125 0.2×	396 0.9×	140	1.8k
Karl T. K. Chen United States	27	926 0.4×	206 0.2×	661 0.9×	208 0.4×	157 0.3×	119	2.4k

Countries citing papers authored by A. Gerl

Since Specialization

Citations

This map shows the geographic impact of A. Gerl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Gerl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Gerl more than expected).

Fields of papers citing papers by A. Gerl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Gerl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Gerl. The network helps show where A. Gerl may publish in the future.

Co-authorship network of co-authors of A. Gerl

This figure shows the co-authorship network connecting the top 25 collaborators of A. Gerl. A scholar is included among the top collaborators of A. Gerl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Gerl. A. Gerl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hentrich, Marcus, et al.. (2020). Improved outcomes in metastatic germ cell cancer: results from a large cohort study. Journal of Cancer Research and Clinical Oncology. 147(2). 533–538. 6 indexed citations

Gerl, A., et al.. (2016). Outcome of patients with metastatic germ cell cancer treated between 2000 and 2013 at two centers in Munich. Annals of Oncology. 27. vi291–vi291. 1 indexed citations

Gerl, A., et al.. (2008). Interstitielle Lupus-Nephritis. DMW - Deutsche Medizinische Wochenschrift. 117(20). 782–786.

Hartmann, J. T., Craig R. Nichols, Jean‐Pierre Droz, et al.. (2002). Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Annals of Oncology. 13(7). 1017–1028. 83 indexed citations

Beyer, J., Sally Stenning, A. Gerl, S.D. Fosså, & W. Siegert. (2002). High-dose versus conventional-dose chemotherapy asfirst-salvage treatment in patients with non-seminomatousgerm-cell tumors: a matched-pair analysis. Annals of Oncology. 13(4). 599–605. 78 indexed citations

Hartmann, J. T., S.D. Fosså, Craig R. Nichols, et al.. (2001). Incidence of Metachronous Testicular Cancer in Patients With Extragonadal Germ Cell Tumors. JNCI Journal of the National Cancer Institute. 93(22). 1733–1738. 121 indexed citations

Gerl, A., et al.. (2001). The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer. 91(7). 1297–1303. 88 indexed citations

Kollmannsberger, Christian, A. Gerl, N. Schleucher, et al.. (2000). Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anti-Cancer Drugs. 11(7). 535–539. 19 indexed citations

Beyer, J., et al.. (1999). High-dose versus conventional-dose first-salvage treatment in nonseminoma: a matched-pair analysis. UCL Discovery (University College London). 11 indexed citations

10.

Semjonow, Axel, et al.. (1999). Tumour markers in prostate cancer: EGTM recommendations. Anticancer Research. 19. 2785–2820. 43 indexed citations

11.

Fosså, Sophie D., Sally Stenning, A. Gerl, et al.. (1999). Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. British Journal of Cancer. 80(9). 1392–1399. 89 indexed citations

12.

Steyerberg, Ewout W., A. Gerl, S.D. Fosså, et al.. (1998). Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer.. Journal of Clinical Oncology. 16(1). 269–274. 72 indexed citations

13.

Steyerberg, Ewout W., H.J. Keizer, Jonathan E. Messemer, et al.. (1997). Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Cancer. 79(2). 345–355. 10 indexed citations

14.

Gerl, A., C. Clemm, N. Schmeller, et al.. (1997). Late relapse of germ cell tumors after cisplatin-based chemotherapy. Annals of Oncology. 8(1). 41–47. 100 indexed citations

15.

Gerl, A. & W. Wilmanns. (1996). Antitumor activity of paclitaxel after failure of high-dose chemotherapy in a patient with late relapse of a non-seminomatous germ cell tumor. Anti-Cancer Drugs. 7(6). 716–718. 9 indexed citations

16.

Gerl, A., C. Clemm, Peter Köhl, & W. Wilmanns. (1994). Testicular T umor afterCisplatin-Based Chemotherapyfor Germ Cell Malignancy. European Urology. 25(3). 216–219. 8 indexed citations

17.

Gerl, A., et al.. (1993). Testicular cancer and Hodgkin disease in the same patient. Cancer. 71(9). 2838–2840. 9 indexed citations

18.

Gerl, A., M. Storck, Andreas Schalhorn, et al.. (1992). Paraneoplastic chronic intestinal pseudoobstruction as a rare complication of bronchial carcinoid.. Gut. 33(7). 1000–1003. 40 indexed citations

19.

Issels, Rolf D., et al.. (1991). Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients. Journal of Cancer Research and Clinical Oncology. 117(S4). S141–S147. 46 indexed citations

20.

Gerl, A., et al.. (1974). Ergebnisse der Ulnarisverlagerung. Acta Neurochirurgica. 30(3-4). 227–246. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact